Mr. Svinlesha:
There were a couple of reasons this specific manuever. Harvard was going to inject more money into Harken to help ensure its viability. They wanted to protect that investment. Had Harken still gone bankrupt then all the assets that Harvard injected would be up for grabs by anybody who Harken owed. They would likely only get back pennies on the dollar. By setting up a partnership, they serve the dual purpose of ensuring Harken’s ongoing viability, and ensuring that they maintain control of their assets.
The lack of subsequent disclosure really isn’t a loophole. It’s a side effect. Disclosure has to end at a certain place for a number of reasons. If it didn’t, then Wrigley had to list your assets in their annual report every time you bought a pack of gum. Clearly that’s excessive.
Additionally, non public entities posess a right to privacy. The Harvard Fund’s research and investments are proprietary. If they fully disclose them at all times it would be as if they were playing poker with their cards facing the wrong way. Other investment firms would be able to take advantage of them. For this same reason most mutual funds only list their holdings in a 6 month retroactive manner.
As a private organization, the Harvard fund had a right to privacy in its partnership. As a public corporation Harken has to disclose it’s dealings. A tough compromise has to take place.
In a transaction like this Harken would have to make a filing with the Sec, have a board vote, and possibly a stockholder vote on what they were doing. They would have to divulge full details of what assets they were placing into the partnership at the time they did it, and that would be divulged in several places, including its financial statements which are sent to all shareholders.
Finally, in the ongoing years that Harken was involved in the partnership, their interest in the partnership would be revealed in several ways on the balance sheet.
The main difference in this kind of thing is twofold:
-
Checks and balances- Harken would hold an interest in an entity that was not held to the same disclosure requirements as Harken itself. Harken investors would know the companies interest in the partnership without any of the specifics of the ongoing operations being revealed. The health of the partnership might be very strong or very weak. Investors trying to analyze the Company would not know, and hence would not have a full and complete picture of Harkens health. While investors do not have full disclosure on this the fact is that they’re not really kept in the dark either. Within the companies 10-k they would be required to disclose the risks and health of their investments in these partnerships, just not with the same stringency they do on the balance sheet.
-
Typically these partnerships are taxed, operate, and subject to different accounting measures than a publically traded corporation, so the companies ongoing interest may be a difficult thing to judge accurately.
The way the law deals with these things to protect investors is by size and interest. If the corporation’s interest is minor, and/or the assets in the partnership are of a de minimis nature than this reduced disclosure is called for. If the interest is large, or the assets are beyond a certain threshhold than the partnership would not escape disclosure, as it would be considered major enough that the public’s need to know outweighs the other considerations.
As for the specifics of this partnership. It is extremely clear and straightforward what it is for, and why it occured. Harken’s interest was a minority one, and at the timeframe we are talking about it was fully disclosed.
No investor in their right mind would have taken issue with this, or the way it was done, or subsequantly reported. The benefits were very large, and the reduced disclosure was minimal.
Finally, neither harken nor Harvard had a choice. The law says that this is the way these things have to be handled. They did not have the option to carry the partnership on the balance sheet.